Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes this week released data from a new report on its Attune knee system, touting the economic benefits and value of procedures with the system to the new value-based healthcare environment.
In the report, researchers analyzed approaches for evaluating primary total knee arthroplasty procedures and assessed data from DePuy’s Attune knee evidence generation program, which includes data from independent studies, national joint registries and both investigator and company initiated studies.
“Based on available data, the Attune Knee appears to be advancing outcomes for patients and creating value for clinicians, providers and payors in a challenging and dynamic healthcare environment,” authors Fisher and Parkin concluded in their report.
Data on the Attune Knee system showed a favorable rate of survivorship, with a revision rate of 1.39% at 3 years from the National Joint Registry for England, Wales, North Ireland and the Isle of man. The revision rate was 0.5% for the Attune cruciate retaining knee and 0.4% for the Attune posterior stabilized knee at 1 year, according to the 2016 Australian Orthopaedic Association National Joint Replacement Registry.
Data from a patient-reported outcome company-led analysis indicated that at 1 year, patients with the Attune knee showed statistically significant improvements in confidence in stability during activity, decreased anterior knee pain, daily activities and quality of life when compared to other knee systems.
Analysis of a US hospital database showed 39% lower odds of patient discharge to a skilled nursing facility for patients with the Attune knee when compared against a Triathlon knee.
“The success of any knee replacement is multifactorial, and the data on the Attune Knee gives me confidence that I’m using a knee replacement that is delivering value for patients and the healthcare system,” Dr. David Fisher of Indianapolis’ OrthoIndy Hospital said in a prepared statement.
“Quality of life, as measured by patient reported outcomes, has been shown to be a driver of cost effectiveness in knee replacement. The evidence that I’ve seen about the effectiveness of the Attune Knee in improving patient reported outcomes suggests it can deliver a better quality of life for patients compared to other leading knee systems. Therefore, the Attune Knee may potentially play a role in helping reduce some of the healthcare and societal costs associated with knee osteoarthritis,” David Parkin of City, University of London said in a press release.
Intuitive Surgical enjoyed a nearly two-decade monopoly in the robot-assisted surgery space. At DeviceTalks West, we'll delve into that history as longtime CEO Gary Guthart tells us how he got his start in medtech, how Intuitive came to enjoy such a commanding lead and what the future holds for medical robotics.
Use code GUTHART to save an additional 10%.